Compare AUDC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUDC | ESPR |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 267.0M | 898.5M |
| IPO Year | 1999 | 2013 |
| Metric | AUDC | ESPR |
|---|---|---|
| Price | $8.80 | $3.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $11.67 | $6.67 |
| AVG Volume (30 Days) | 92.8K | ★ 5.3M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | ★ 15.76 | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $244,553,000.00 | ★ $303,802,000.00 |
| Revenue This Year | $2.98 | $26.11 |
| Revenue Next Year | $3.40 | N/A |
| P/E Ratio | $19.02 | ★ N/A |
| Revenue Growth | 0.15 | ★ 2.83 |
| 52 Week Low | $8.01 | $0.69 |
| 52 Week High | $12.72 | $4.13 |
| Indicator | AUDC | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 50.54 |
| Support Level | $8.79 | $3.87 |
| Resistance Level | $8.96 | $4.05 |
| Average True Range (ATR) | 0.20 | 0.20 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 14.97 | 15.00 |
AudioCodes Ltd develops and sells onverged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.